{
  "docId": "019de071-4ec1-761e-bce7-779cb9a1fe78",
  "docSlug": "bd64755c9d094dce862ec77cfb2b1978",
  "documentTitle": "TScan Therapeutics | IPO Presentation Deck | 43 slides",
  "authorId": "tscan-therapeutics",
  "authorName": "TScan Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 43,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The chart shows a clear upward trend in HCT procedures from 2000 to 2018, segmented by indication (AML, MDS, ALL).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-4ec1-761e-bce7-779cb9a1fe78/21",
  "deckHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78",
  "deckJsonHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78.json",
  "deckAnchorHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.58,
        "y": 0.75
      },
      "kind": "callout",
      "text": "The TSC-100 program is designed to address a large, growing pool of addressable patients in key indications",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49f9d9fb-eddc-4e3e-8f4d-6999a6090e31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.08,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Number of Allogeneic HCTs in Key TSC-100 Program Indications",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "767d9d1b-06e6-4f5a-b655-fcd7ba39ef88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.38,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "list",
      "text": "~7K patients currently receive allo-HCT in key indications in the U.S. and would be candidates for the TSC-100 program. ~40% of patients would be eligible for TSC-100 and TSC-101. HCT use has been increasing for the treatment of priority hematologic malignancies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "364ccb65-63be-43d2-8623-3c6bb37e49f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.15,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Center for International Blood and Marrow Transplant Research (CIBMTR).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40c5d7d1-8760-4990-a4b7-28e9b667bb6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Liquid tumor program addresses a large and growing market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3da2ee3e-4134-4f09-aa74-9c277fb551e6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 20,
      "beatId": "7130cea9-e445-4d6c-813d-cefc1a9760e1",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents a clear problem statement and market sizing.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "becd6f83-d37d-46f9-a0e0-b7ce2b7976e8",
      "evidence": "The document presents a clear problem statement and market sizing, highlighting the need for effective cancer therapies.",
      "position": 0,
      "objective": "What is the cost of inaction for patients with cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}